Screener
Tarsus Pharmaceuticals, Inc. TARS Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,271,347 shares issued and outstanding at June 30, 2026 (unaudited); 42,553,931 shares issued and outstanding at December 31, 2025 | 6 | 6 |
| Additional paid-in capital | 799,429 | 769,667 |
| Accumulated other comprehensive income (loss) | (557) | 381 |
| Accumulated deficit | (452,146) | (426,628) |
| Total stockholders’ equity | 346,732 | 343,426 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s common stock par value per share?
- Tarsus Pharmaceuticals, Inc. (TARS) reported common stock par value per share of $0.00 in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s common stock par value per share changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s common stock par value per share?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude